INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
Review on Potential combination therapy in treatment of Parkinson disease and related Dementia Disorders: Emphasises on Safinamide
Authors Name:
Abhishek Saini
, Prince Thakur , Nikhil Sharma , Dr. Amar Deep Ankalgi , Amit Kumar Kaundal
Unique Id:
IJSDR2210139
Published In:
Volume 7 Issue 10, October-2022
Abstract:
With a focus on safinamide, the authors address management difficulties in PD and related Dementia disorders and present an overview of the current pharmacological strategic actions. Levodopa, Dopamine agonists, MAO-B inhibitors, NMDA Receptor agonists, and other inhibitors of enzymes are among some of the main therapeutic strategies used today to control Parkinson disease. With the rise in number of diverse neurodegenerative diseases that lead to dementia syndromes and have their own unique neurochemical pathologies. Since what works for one person may not work for another or, in the worst-case scenario, may make things worse, this has significant therapy implications. Safinamide, an α-aminoamide with multiple dopaminergic and non-dopaminergic ways of action, such as inhibition of sodium (Na+) channel, Inhibition of monoamine oxidase-B (MAO-B) and regulation of stimulated glutamate release can be helpful in the control of Parkinson Disease and related dementia disorders. According to cross-sectional research, up to 40% of PD patients experience dementia, which has a cumulative prevalence of 78% over 8 years and involves executive function and attention deficiencies, whereas memory dysfunction is caused by defective storage and retrieval mechanisms. Unified Parkinson's Disease Rating Scale’s Scores are improved by safinamide when used alone or in conjunction with dopamine agonists and potential combination therapy can be used for treatment of related dementia disorders. With the similarities in the arise of various dementia disorders and multiple mode of actions of Safinamide, it can be coined that the potential of Safinamide in conjugate with the other drugs can potentially give a new hope in PD and related dementia disorders.
"Review on Potential combination therapy in treatment of Parkinson disease and related Dementia Disorders: Emphasises on Safinamide", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 10, page no.818 - 824, October-2022, Available :http://www.ijsdr.org/papers/IJSDR2210139.pdf
Downloads:
000337348
Publication Details:
Published Paper ID: IJSDR2210139
Registration ID:202319
Published In: Volume 7 Issue 10, October-2022
DOI (Digital Object Identifier):
Page No: 818 - 824
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn